DDInter1125 DDInter899
Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Maraviroc {u} (Compound) binds {v} (Gene) CYP3A4
Maraviroc {u} (Compound) upregulates {v} (Gene) CNPY3
Maraviroc {u} (Compound) is included by {v} (Pharmacologic Class) Chemokine Co-receptor 5 Antagonists
Maraviroc {u} (Compound) downregulates {v} (Gene) NPDC1
Maraviroc {u} (Compound) causes {v} (Side Effect) Herpes virus infection
Maraviroc {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Minoxidil
Maraviroc {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Maraviroc {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Maraviroc {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Maraviroc (Compound) binds CYP3A4 (Gene)
Maraviroc (Compound) upregulates CNPY3 (Gene)
Maraviroc (Compound) is included by Chemokine Co-receptor 5 Antagonists (Pharmacologic Class)
Maraviroc (Compound) downregulates NPDC1 (Gene)
Maraviroc (Compound) causes Herpes virus infection (Side Effect)
Maraviroc may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil
Maraviroc may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Maraviroc may lead to a major life threatening interaction when taken with Leflunomide
Maraviroc may lead to a major life threatening interaction when taken with Idelalisib